◎ Sugi Atlas

Atlas / Drug / Sorbinil

Sorbinil

drug
On this page

Also known as CP-45,634CP-45634NSC-355082SorbiniloSID29215399SID144205232SID170466611

Summary

Sorbinil (CHEMBL266497) is a phase-3 clinical-stage small-molecule EC 1.1.1.21 (aldehyde reductase) inhibitor targeting AKR1B1; indicated across 1 condition including diabetic retinopathy.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Small molecule
  • Targets: 1 (AKR1B1)
  • Indications: 1 condition
  • Clinical trials: 1
  • Chemistry: 236.2 Da · C11H9FN2O3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL266497
NameSorbinil
TypeSmall molecule
Max phase3
FDA approvedno
PubChem CID337359
ChEBICHEBI:102029
Molecular formulaC11H9FN2O3
Molecular weight236.2
InChIKeyLXANPKRCLVQAOG-NSHDSACASA-N

SMILES: C1COC2=C([C@]13C(=O)NC(=O)N3)C=C(C=C2)F

IUPAC name: (4S)-6-fluorospiro[2,3-dihydrochromene-4,5’-imidazolidine]-2’,4’-dione

ChEBI definition: An azaspiro compound having a monofluoro-substituted chromane skeleton spiro-linked to an imidazolidinedione ring.

Pharmacological roles (ChEBI): EC 1.1.1.21 (aldehyde reductase) inhibitor, antioxidant.

Also known as: CP-45,634, CP-45634, NSC-355082, Sorbinil, Sorbinilo, sorbinil, SID29215399, SORBINIL, SID144205232, SID170466611

Patent coverage: 575 distinct patent families (2,026 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,024 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
AKR1B1aldo-keto reductase family 1 member BInhibition5.271.1%P15121

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Microtubule-associated protein tau, Aldo-keto reductase family 1 member B1, Aldo-keto reductase family 1 member A1, Aldo-keto reductase family 1 member B1, Aldo-keto reductase family 1 member B1, Aldo-keto reductase family 1 member A1, Aldo-keto reductase family 1 member A1, Aldo-keto reductase family 1 member B1, Aldo-keto reductase family 1 member B10.

Bioactivity

ChEMBL activities: 88 potent at pChembl ≥ 5 of 89 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
P079437.77IC5017nMCHEMBL_ACT_1116355
P079437.77IC5017nMCHEMBL_ACT_900843
P079437.7IC5020nMCHEMBL_ACT_313783
P079437.54IC5029nMCHEMBL_ACT_18152799
P516357.54IC5029nMCHEMBL_ACT_96690
AKR1B17.17IC5067nMCHEMBL_ACT_1231933
AKR1B17.16IC5070nMCHEMBL_ACT_3121835
P079437.16IC5070nMCHEMBL_ACT_330995
P079437.14IC5073nMCHEMBL_ACT_166635
P079437IC50100nMCHEMBL_ACT_354978
AKR1B16.92IC50120nMCHEMBL_ACT_83827
AKR1B16.85IC50140nMCHEMBL_ACT_1618319
AKR1B16.85IC50140nMCHEMBL_ACT_171008
P161166.82IC50150nMCHEMBL_ACT_406559
AKR1B16.77IC50170nMCHEMBL_ACT_219714
P079436.75IC50180nMCHEMBL_ACT_70603
P079436.72IC50190nMCHEMBL_ACT_330994
P079436.7IC50200nMCHEMBL_ACT_406560
P079436.64IC50230nMCHEMBL_ACT_1278080
P079436.6IC50250nMCHEMBL_ACT_1017936
P079436.6IC50250nMCHEMBL_ACT_12631604
P079436.6IC50250nMCHEMBL_ACT_13413155
P079436.6IC50250nMCHEMBL_ACT_14581564
P079436.6IC50249nMCHEMBL_ACT_2189332
P079436.6IC50250nMCHEMBL_ACT_3121834
AKR1B16.6IC50249nMCHEMBL_ACT_3265990
P079436.6IC50250nMCHEMBL_ACT_3559852
AKR1B16.6IC50250nMCHEMBL_ACT_359144
P079436.55IC50280nMCHEMBL_ACT_490200
P079436.37IC50430nMCHEMBL_ACT_16834652

Target pathways

Aggregated over 1 target gene(s): AKR1B1.

Top Reactome pathways

9 total, by targets touching each:

PathwayTargetsGenes
Metabolism1AKR1B1
Metabolism of steroid hormones1AKR1B1
Pregnenolone biosynthesis1AKR1B1
Metabolism of lipids1AKR1B1
Fructose metabolism1AKR1B1
Fructose biosynthesis1AKR1B1
Galactose catabolism1AKR1B1
Metabolism of carbohydrates and carbohydrate derivatives1AKR1B1
Metabolism of steroids1AKR1B1

Dominant GO biological processes

GO termTargets
retinoid metabolic process1
epithelial cell maturation1
renal water homeostasis1
carbohydrate metabolic process1
C21-steroid hormone biosynthetic process1
regulation of urine volume1
negative regulation of apoptotic process1
daunorubicin metabolic process1
doxorubicin metabolic process1
fructose biosynthetic process1
cellular hyperosmotic salinity response1
metanephric collecting duct development1
lipid metabolic process1
prostaglandin metabolic process1
retinol metabolic process1

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
diabetic retinopathy3MONDO:0005266EFO:0003770

Clinical trials

Total trials: 1.

Phase distribution

PhaseTrials
PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00000159PHASE3COMPLETEDSorbinil Retinopathy Trial (SRT)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

36 molecules share ≥1 primary target. Top 36 by shared-target count:

MoleculeSourceStatusShared targets
FOLIC ACIDChEMBL + PubChemPhase 4 (approved)AKR1B1
EPALRESTATChEMBLPhase 4 (approved)AKR1B1
ESTRADIOLChEMBLPhase 4 (approved)AKR1B1
ESTRONEChEMBLPhase 4 (approved)AKR1B1
INDOMETHACINChEMBLPhase 4 (approved)AKR1B1
MEFENAMIC ACIDChEMBLPhase 4 (approved)AKR1B1
NITAZOXANIDEChEMBLPhase 4 (approved)AKR1B1
SULINDACChEMBLPhase 4 (approved)AKR1B1
TOLMETINChEMBLPhase 4 (approved)AKR1B1
TOLRESTATChEMBLPhase 4 (approved)AKR1B1
CAFFEIC ACIDChEMBLPhase 3AKR1B1
CURCUMINChEMBLPhase 3AKR1B1
GOSSYPOLChEMBLPhase 3AKR1B1
QUERCETINChEMBLPhase 3AKR1B1
RANIRESTATChEMBLPhase 3AKR1B1
RESVERATROLChEMBLPhase 3AKR1B1
ALRESTATINChEMBLPhase 2AKR1B1
AZD1981ChEMBLPhase 2AKR1B1
CHLOROGENIC ACIDChEMBLPhase 2AKR1B1
ELLAGIC ACIDChEMBLPhase 2AKR1B1
FIDARESTATChEMBLPhase 2AKR1B1
FLUFENAMIC ACIDChEMBLPhase 2AKR1B1
GENISTEINChEMBLPhase 2AKR1B1
HYMECROMONEChEMBLPhase 2AKR1B1
IMIRESTATChEMBLPhase 2AKR1B1
ISOQUERCETINChEMBLPhase 2AKR1B1
LIDORESTATChEMBLPhase 2AKR1B1
LUTEOLINChEMBLPhase 2AKR1B1
MINALRESTATChEMBLPhase 2AKR1B1
OXEPINACChEMBLPhase 2AKR1B1
PONALRESTATChEMBLPhase 2AKR1B1
SEPRANOLONEChEMBLPhase 2AKR1B1
TIOPINACChEMBLPhase 2AKR1B1
URSOLIC ACIDChEMBLPhase 2AKR1B1
ZENARESTATChEMBLPhase 2AKR1B1
ZOPOLRESTATChEMBLPhase 2AKR1B1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 29

This page pulls from 29 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot